CD8A and neoplasm: Previous studies demonstrated that tumor-specific effector CD8 + T cells are required for radiotherapy-induced mobilization of tumor-specific immunity [32], while in our mouse experiments, we found out CD8 + T cells and DCs increased in the tumor treated with combination therapy.